Inclisiran, a Potent Lipid Lowering Treatment for Reaching LDL Goals on Top of Statins and Ezetimibe: A Single User Experiences

Main Article Content

Timon Zupanc
Jurij Krajačič
Boris Krajačič
Oskar Zupanc
Matjaz Bunc

Abstract

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, and reducing LDL cholesterol is a key strategy in lowering cardiovascular risk. Inclisiran, a small interfering RNA that targets PCSK9, is an effective lipid-lowering treatment.


AIM: This study evaluates the long-term efficacy of inclisiran in patients with high cardiovascular risk who fail to reach LDL goals despite statin and ezetimibe therapy.


METHODS: A total of 33 patients with high-risk atherosclerotic disease and elevated LDL cholesterol levels, despite maximal statin/ezetimibe therapy or patients who couldn't tolerate statins, were administered inclisiran at baseline with 21 patients receiving a second dose at 3 months. Lipid profiles were measured at baseline, 3 months after first dose, and 3 months after second dose. The primary outcome was the change in LDL-C levels from baseline to post-treatment.


RESULTS: Inclisiran significantly reduced LDL-C levels from a baseline mean of 2.66 mmol/L to 1.49 mmol/L after the first dose (p < 0.001). A total of 73.0% of patients achieved LDL-C levels below 1.8 mmol/L, 57.7% below 1.4 mmol/L, and 34.6% below 1.0 mmol/L, with 42.3% experiencing a reduction of more than 50% after the first dose. These reductions were maintained after the second dose, with LDL-C levels remaining significantly lower than baseline.


CONCLUSION: Inclisiran provides significant and sustained LDL-C reductions in patients with high cardiovascular risk and represents an effective long-term treatment option for reducing cardiovascular risk.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Zupanc T, Krajačič J, Krajačič B, Zupanc O, Bunc M. Inclisiran, a Potent Lipid Lowering Treatment for Reaching LDL Goals on Top of Statins and Ezetimibe: A Single User Experiences. SEE J Cardiol [Internet]. 2024 Nov. 17 [cited 2026 Nov. 17];5:30-3. Available from: https://seejca.eu/index.php/seejca/article/view/6073
Section
General Cardiology

References

1. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018 Nov 10;392(10159):2052-2090. https://doi.org/10.1016/S0140-6736(18)31694-5. Epub 2018 Oct 16. PMID: 30340847; PMCID: PMC6227505.

2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. https://doi.org/10.1093/eurheartj/ehx144 PMID: 28444290; PMCID: PMC5837225. 3. Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. https://doi.org/10.1016/j.jacc.2020.12.058. PMID: 33663735.

4. Banach M, Reiner Z, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M, et al 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A position paper of the International Lipid Expert Panel (ILEP). Drugs, 2024, in press. https://doi.org/10.1007/s40265-024-02105-5

5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25). Erratum in: Circulation. 2023 Aug 15;148(7). https://doi.org/10.1161/CIR.0000000000001172. PMID: 30586774; PMCID: PMC7403606.

6. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. https://doi.org/10.1093/eurheartj/ehac458. PMID: 34458905.

7. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. Erratum in: Eur Heart J. 2024 Apr 1;45(13):1145. https://doi.org/10.1093/eurheartj/ehad870. PMID: 37622654.

8. Lee B, Hong SJ, Rha SW, Heo JH, Hur SH, Choi HH, et al. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial. Atherosclerosis. 2023 Dec;386:117373. https://doi.org/10.1016/j.atherosclerosis.2023.117373. Epub 2023 Nov 10. PMID: 37995599.

9. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-1722. Epub 2017 Mar 17. https://doi.org/10.1056/NEJMoa1615664 PMID: 28304224.

10. Inclisiran (Leqvio). In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. 2022 Jun 20. Available from: https://www.ncbi.nlm.nih.gov/books/NBK595412/

11. Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, et al. An "Inclisiran First" strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024 May 21;83(20):1939-1952. https://doi.org/10.1016/j.jacc.2024.03.382. Epub 2024 Apr 7. PMID: 38593947.

12. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. https://doi.org/10.1056/NEJMoa1912387. Epub 2020 Mar 18. PMID: 32187462.

13. Banach M, Reiner Z, Cicero AFG, Sabouret P, Viigimaa M, Sahebkar A, et al. 2022: the year in cardiovascular disease - the year of upfront lipid-lowering combination therapy. Arch Med Sci. 2022 Nov 7;18(6):1429-1434. https://doi.org/10.5114/aoms/156147. PMID: 36457968; PMCID: PMC9710261.

14. Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit: a consensus statement from the National Lipid Association. J Clin Lipidol. 2019 Jul-Aug;13(4):525-537. https://doi.org/10.1016/j.jacl.2019.05.005. Epub 2019 May 16. PMID: 31281070.

Similar Articles

<< < 1 2 3 > >> 

You may also start an advanced similarity search for this article.